Price, DavidHenley, WilliamCarter, VictoriaSkinner, DerekVella, RebeccaPapi, AlbertoFabbri, Leonardo MKerstjens, Huib AMRoche, NicolasSingh, DaveVogelmeier, Claus FŞen, ElifDelfini Cançado, José EduardoKots, MaximNudo, ElenaBarile, SaraGeorges, George2023-03-282023-03-282022-12-22Price, D, Henley, W, Carter, V, Skinner, D, Vella, R, Papi, A, Fabbri, L M, Kerstjens, H AM, Roche, N, Singh, D, Vogelmeier, C F, Şen, E, Delfini Cançado, J E, Kots, M, Nudo, E, Barile, S & Georges, G 2022, 'Commencement of fixed dose ICS of varying particle size as a predictor of pneumonia in COPD patients', Annual Scientific Meetings of The Australia and New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand, Christchurch, New Zealand, 25/03/23 - 28/03/23.conferencehttps://hdl.handle.net/2164/20357Grant Support: This study was funded by Chiesi Farmaceutici S.p.A. David Price has grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Theravance and UK National Health Service; is a peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation programme, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline.319545engparticle sizeICSpneumoniaCOPDextrafineR MedicineRConference item